Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco

Hassan Errihani, Narjiss Berrada, Meryem El Bachiri, Hassan Jouhadi, Omar Kabbaj, Mouna Bourhafour, Abdellatif Benider, Mouna Khouchani, Ghizlane Belbaraka, Abdelkader Acharki, Redouane Samlali, Kunvar Harsh Upveja

Open source

DOI
10.1186/s12885-026-16005-2
Published
2026-04-28
Container
BMC Cancer
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12885-026-16005-2,
  title = {Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco},
  author = {Hassan Errihani and Narjiss Berrada and Meryem El Bachiri and Hassan Jouhadi and Omar Kabbaj and Mouna Bourhafour and Abdellatif Benider and Mouna Khouchani and Ghizlane Belbaraka and Abdelkader Acharki and Redouane Samlali and Kunvar Harsh Upveja},
  year = {2026},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-026-16005-2},
  url = {https://doi.org/10.1186/s12885-026-16005-2}
}

RIS

TY  - JOUR
TI  - Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco
AU  - Hassan Errihani
AU  - Narjiss Berrada
AU  - Meryem El Bachiri
AU  - Hassan Jouhadi
AU  - Omar Kabbaj
AU  - Mouna Bourhafour
AU  - Abdellatif Benider
AU  - Mouna Khouchani
AU  - Ghizlane Belbaraka
AU  - Abdelkader Acharki
AU  - Redouane Samlali
AU  - Kunvar Harsh Upveja
PY  - 2026
JO  - BMC Cancer
DO  - 10.1186/s12885-026-16005-2
UR  - https://doi.org/10.1186/s12885-026-16005-2
ER  - 

APA

Errihani, H., Berrada, N., Bachiri, M. E., Jouhadi, H., Kabbaj, O., Bourhafour, M., Benider, A., Khouchani, M., Belbaraka, G., Acharki, A., Samlali, R., & Upveja, K. H. (2026). Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco. BMC Cancer. https://doi.org/10.1186/s12885-026-16005-2

Source records